Moderna projects 2025 product sales of approximately $1.9 billion, exceeding the midpoint of its prior $1.6 billion to $2 billion range by roughly $100 million. This forecast places the company near the upper quartile of its revenue guidance, reflecting steady demand for its authorized mRNA-based vaccines and pipeline candidates expected to contribute incremental sales through late-stage clinical readouts and potential regulatory approvals.

The company has raised its 2025 GAAP operating expense estimate by $200 million, now targeting a range of $5 billion to $5.2 billion. This revision reflects expanded investments in manufacturing capacity expansion across its Swiss and U.S. sites, accelerated R&D spending on respiratory and immuno-oncology programs, and higher clinical trial activity that counters cost containment measures implemented earlier in the year.

Moderna forecasts a year-end 2025 cash and short-term investments balance of approximately $8.1 billion, inclusive of a $600 million drawdown from its newly established $1.5 billion term loan facility. This financing provides non-dilutive liquidity to support late-stage trials, global supply chain resilience, and potential business development transactions without immediate equity issuance.

Looking beyond 2025, Moderna reaffirms expectations for up to 10% revenue growth in 2026, driven by scaling of next-generation seasonal respiratory vaccines, anticipated label expansions for its cytomegalovirus candidate, and initial contributions from in-house oncology mRNA constructs. The company’s confidence in double-digit growth underscores its transition from pandemic-era volumes toward a diversified product portfolio.